secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nautilus Biotechnology, Inc. (NAUT)
CIK:        0001808805
Form:       8-K/A
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0001808805-22-000108
Event type: leadership
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Nautilus appoints Karen Akinsanya to Nominating and Governance Committee
------------------------------------------------------------------------

- Appointment effective October 27, 2022; committee now includes McIlwain (Chair), Pande, and Akinsanya.
- Akinsanya joined the Board in March 2022; committee assignment was previously undetermined.
- This amendment updates the original 8-K filed March 31, 2022 regarding Akinsanya's directorship.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808805/000180880522000108/0001808805-22-000108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808805/000180880522000108/naut-20220330.htm
  HTML page:      https://secwatch.observer/filing/0001808805-22-000108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer